Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TLSA | US
0.06
4.88%
Healthcare
Biotechnology
31/12/2023
24/04/2026
1.29
1.25
1.30
1.21
Tiziana Life Sciences Ltd a biotechnology company focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401) a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's graft versus host ulcerative colitis multiple sclerosis type-1 diabetes inflammatory bowel psoriasis and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201) a small molecule inhibitor of various cyclin-dependent kinases tropomycin receptor kinases and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501) a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London the United Kingdom.Kingdom.
View LessLow Market Beta (-0.4 to 0.8)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
86.0%1 month
72.9%3 months
73.0%6 months
73.1%-
-
16.12
-
-
-5.98
-
-
-15.79M
130.95M
130.95M
-
-
-
-
-181.23
0.29
0.10
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.28
Range1M
0.28
Range3M
0.63
Rel. volume
0.93
Price X volume
205.02K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| TransCode Therapeutics Inc. Common Stock | RNAZ | Biotechnology | 8.52 | 143.72M | -1.73% | 0.00 | 17.19% |
| ELEDON PHARMACEUTICALS INC | ELDN | Biotechnology | 3.465 | 143.39M | -3.48% | 6.60 | -7.70% |
| BriaCell Therapeutics Corp. Common Shares | BCTX | Biotechnology | 3.88 | 139.25M | 4.02% | n/a | 0.00% |
| Connect Biopharma Holdings Limited American Depositary Shares | CNTB | Biotechnology | 2.52 | 139.24M | 0.00% | n/a | 0.29% |
| Citius Pharmaceuticals Inc | CTXR | Biotechnology | 0.77 | 139.16M | -17.47% | n/a | 0.37% |
| Achieve Life Sciences Inc | ACHV | Biotechnology | 4.02 | 138.05M | -3.13% | n/a | 41.73% |
| Mawson Infrastructure Group Inc. Common Stock | MIGI | Biotechnology | 7.37 | 136.74M | 23.45% | n/a | 571.64% |
| AVTX | AVTX | Biotechnology | 13.92 | 135.02M | -5.63% | n/a | -80.47% |
| Anthem Inc. CORP UNIT 050118 | ANTX | Biotechnology | 4.34 | 129.52M | 1.40% | n/a | 0.00% |
| QSI | QSI | Biotechnology | 0.9058 | 128.95M | -3.70% | n/a | 0.71% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 36.11 | 103.70M | 0.00% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.11 | 99.53M | 1.16% | 9.09 | 39.79% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.765 | 73.67M | 1.69% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 3.9 | 70.43M | 6.56% | n/a | 5.48% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 21.77 | 33.16M | -2.81% | n/a | 204.46% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.57 | 11.01M | -3.37% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5165 | 7.55M | -0.67% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.38 | 3.52M | 0.23% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.199 | 1.89M | 1.38% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 1.27 | 699.77K | -6.62% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -5.98 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 16.12 | 15.55 | Par |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 73.04 | 72.80 | Par |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 130.95M | 3.66B | Emerging |